- Home
- SYBT vs HCM Comparison
SYBT vs HCM Comparison
Compare SYBT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYBT
- HCM
- Stock Information
- Founded
- SYBT 1904
- HCM 2000
- Country
- SYBT United States
- HCM Hong Kong
- Employees
- SYBT N/A
- HCM N/A
- Industry
- SYBT Major Banks
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- SYBT Finance
- HCM Health Care
- Exchange
- SYBT Nasdaq
- HCM Nasdaq
- Market Cap
- SYBT 2.3B
- HCM 2.6B
- IPO Year
- SYBT N/A
- HCM N/A
- Fundamental
- Price
- SYBT $71.54
- HCM $15.99
- Analyst Decision
- SYBT Hold
- HCM Sell
- Analyst Count
- SYBT 3
- HCM 1
- Target Price
- SYBT $83.67
- HCM $13.75
- AVG Volume (30 Days)
- SYBT 105.8K
- HCM 58.9K
- Earning Date
- SYBT 10-22-2025
- HCM 08-07-2025
- Dividend Yield
- SYBT 1.68%
- HCM N/A
- EPS Growth
- SYBT 22.18
- HCM N/A
- EPS
- SYBT 4.35
- HCM 0.53
- Revenue
- SYBT $364,546,000.00
- HCM $602,197,000.00
- Revenue This Year
- SYBT $16.83
- HCM $1.39
- Revenue Next Year
- SYBT $5.12
- HCM $16.66
- P/E Ratio
- SYBT $16.96
- HCM $5.75
- Revenue Growth
- SYBT 11.32
- HCM N/A
- 52 Week Low
- SYBT $57.12
- HCM $11.51
- 52 Week High
- SYBT $83.83
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- SYBT 32.82
- HCM 45.89
- Support Level
- SYBT $73.70
- HCM $15.94
- Resistance Level
- SYBT $75.68
- HCM $18.30
- Average True Range (ATR)
- SYBT 2.08
- HCM 0.37
- MACD
- SYBT -0.67
- HCM -0.02
- Stochastic Oscillator
- SYBT 1.30
- HCM 18.64
About SYBT Stock Yards Bancorp Inc.
Stock Yards Bancorp Inc operates as a bank. The bank has two reportable operating segments namely Commercial Banking and Wealth Management and Trust. Its services include loan and deposit services, cash management services, securities brokerage activities, mortgage origination, and others. It generates the majority of its revenue from the Commercial Banking segment.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.